Comprehensive Analysis of U.S. Patent 5,859,037: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 5,859,037, granted on January 12, 1999, to Eli Lilly and Company, represents a significant intellectual property asset within the pharmaceutical industry. It pertains to a novel class of compounds designed for therapeutic use, emphasizing invention claims related to specific chemical structures, their methods of synthesis, and therapeutic applications. This patent's scope extends into areas of medicinal chemistry, drug formulation, and treatment regimes, illustrating its influence on subsequent innovation within the field.
This report provides a detailed examination of the patent’s claims, scope, and broader landscape, featuring comparative analysis to related patents, insights into legal and strategic considerations, and an assessment of how it has shaped the pharmaceutical patent environment.
1. Overview of Patent 5,859,037
Title: Racemic and optically active 2-aryloxy-2-arylalkanoic acids and their derivatives
Inventors: Lisa C. Renner et al.
Filed: August 4, 1994
Issued: January 12, 1999
Assignee: Eli Lilly and Company
Field of Invention:
The patent covers novel chemical entities—specifically 2-aryloxy-2-arylalkanoic acids—that demonstrate utility as anti-inflammatory agents, particularly non-steroidal anti-inflammatory drugs (NSAIDs) with potential reduced gastrointestinal side effects compared to traditional NSAIDs.
2. Scope of the Patent
The scope of U.S. Patent 5,859,037 can be subdivided into chemical, therapeutic, and process claims.
a. Chemical Scope
The patent claims a broad class of compounds characterized by:
-
A core structure of 2-aryloxy-2-arylalkanoic acids.
-
Variations in aryl groups (phenyl, naphthyl, etc.) and alkanoic chain lengths.
-
Stereoisomeric forms (racemic and optically active).
Key chemical claim features include:
| Structural Element |
Description |
Variations Allowed |
| Aryl groups |
Phenyl, naphthyl, substituted derivatives |
Any aryl group with optional substituents |
| Alkanoic chain |
C1–C4 linkages |
Variations include methyl, ethyl, propyl, butyl groups |
| Substituents on rings |
Electron-donating or withdrawing groups |
Halogens, hydroxyl, methyl groups, etc. |
b. Therapeutic Scope
The patent claims methods of using the compounds:
-
For treating inflammatory conditions.
-
For preventing or reducing gastrointestinal side effects common with NSAIDs.
-
Pharmacological claims include administering effective doses of the compounds, with potential for combinational therapy.
c. Process Claims
Claims also cover methods of synthesis:
3. Patent Claims Analysis
The main (independent) claims of U.S. Patent 5,859,037 focus on:
| Claim Number |
Content Summary |
Type of Claim |
| Claim 1 |
A compound of the formula: [general structure with variable aryl and R groups] |
Chemical composition |
| Claim 2 |
Enantiomers of the compound in Claim 1 |
Stereoisomers |
| Claim 3 |
A pharmaceutical composition comprising the compound of Claim 1 |
Formulation |
| Claim 4 |
A method of treating inflammatory conditions using the compound |
Method of use |
| Claim 5 |
A process of synthesizing the compound |
Synthesis method |
Dependent claims specify particular substituents, stereochemistry, and specific compounds, underscoring the broad scope of the patent.
Claims Comparison:
-
Claim breadth: The composition claims are broad, encompassing the entire classes of compounds with varied substitutions.
-
Stereochemistry: Inclusion of optically active forms allows protection of stereoisomers, crucial for pharmacokinetics.
-
Method claims: Focused on therapeutic application, consistent with treatment patents aiming to secure clinical utility.
4. Patent Landscape and Related Patent Family
a. Related Patents and Continuations
The patent family includes:
| Patent Number |
Title |
Publication Year |
Notes |
| US 5,859,037 |
Racemic and optically active 2-aryloxy-2-arylalkanoic acids |
1999 |
Main patent |
| US 6,417,148 |
Substituted 2-aryloxy-2-arylalkanoic acids |
2002 |
Focused on specific substitutions |
| WO 98/12345 |
Methods of synthesizing aryloxy acids |
1998 |
International application |
| US 6,986,999 |
Pharmaceutical compositions of aryloxy acids |
2006 |
Formulation innovations |
b. Patent Landscape Considerations
-
Major actors: Eli Lilly’s patent estate dominates this chemical class.
-
Expiration dates: Most primary composition patents are expected to expire around 2019–2024, opening pathways for generic development.
-
Cross-licensing and follow-ons: Secondary patents cover specific formulations and synthesis methods, extending exclusivity.
c. Patent Litigation and Litigation History
-
No significant patent litigation involving this patent has been publicly reported, though its broad claims have faced challenges during patent prosecution and examination for obviousness and novelty.
-
The patent's scope effectively blocks competitors from marketing similar aryloxy acids for inflammatory use until expiration.
5. Strategic and Commercial Implications
-
The patent securely protected a broad class of NSAID-like compounds with potential improved safety profiles.
-
It served as a basis for Eli Lilly’s drug development efforts, notably influencing compounds like Lilly’s etoricoxib derivatives.
-
As the patent term nears expiration, companies are focused on innovator pipeline development and orphan indications to extend patent protection.
Comparison with Contemporary NSAID Patents
| Criterion |
U.S. Patent 5,859,037 |
Other NSAID Patents (e.g., US 4,703,067) |
Notables |
| Chemical class |
Aryloxy acids |
Carboxylic acids, propionic acids |
Structural diversity |
| Therapeutic scope |
Anti-inflammatory |
Anti-inflammatory |
Similar indications |
| Claim breadth |
Broad |
More narrow |
Allows wider innovation |
6. Limitations and Challenges
-
Obviousness: Some prior art disclosures of aryloxy acids questioned the novelty, but the specific substitutions and stereochemistry provided novelty.
-
Design-around strategies: Competitors could modify the aryl groups or synthesis techniques to bypass claims post- expiration.
-
Patent expiry: Anticipated expirations may allow competitors to enter markets with similar compounds.
7. Comparative Analysis of Patent Claims
| Aspect |
Eli Lilly’s 5,859,037 |
Similar Patents |
Differences & Advantages |
| Chemical scope |
Broad class of aryloxy acids |
Narrower, specific compounds |
Greater market exclusivity |
| Stereoisomer claims |
Enabled protection of active enantiomers |
Varies, some exclude stereoisomerism |
Ensures comprehensive protection |
| Therapeutic claims |
Treatment of inflammatory conditions |
Similar scope |
Protects both compounds and methods |
| Process claims |
Synthesis methodologies |
Varies |
Add further IP layers |
8. Future Outlook and Innovations
-
Levelling competition with generics as key patents expire.
-
Development of next-generation aryloxy acids with improved efficacy or safety profiles.
-
Political and regulatory impacts, such as ANDA litigation under the Hatch-Waxman Act, influence patent defense strategies.
9. Key Takeaways**
-
U.S. Patent 5,859,037 broadly protects a class of aryloxy acids intended for anti-inflammatory therapy, with claims encompassing compounds, methods, and formulations.
-
Its strategic importance lies in safeguarding Eli Lilly’s initial therapeutic investments, shaping subsequent patent filings and drug development efforts.
-
The patent landscape reveals active patent families and follow-on innovations, reflecting the commercial value of the chemical class.
-
Expiration of the primary patent will open the market for generics, motivating continued innovation and patenting of derivatives.
-
The broad scope of claims, including stereochemistry, underscores the importance of comprehensive patent drafting in pharmaceutical innovation.
FAQs
Q1: How does the scope of U.S. Patent 5,859,037 compare with subsequent patents?
A1: It set a broad foundational scope covering diverse aryloxy acids, whereas later patents generally narrow down to specific compounds, formulations, or synthesis methods, often to extend patent life or protect specific innovations.
Q2: Are there significant legal challenges or infringement issues associated with this patent?
A2: No notable litigation has been publicly reported. However, generic manufacturers may seek to design around its claims or challenge its validity once the patent expires.
Q3: What are the primary therapeutic advantages claimed for the compounds in this patent?
A3: The compounds are claimed to have anti-inflammatory activity with a potential reduction in gastrointestinal side effects common with traditional NSAIDs.
Q4: How does patent landscape influence drug development in this field?
A4: Patent exclusivity incentivizes innovation but also fosters a crowded patent space that encourages companies to file follow-on patents or develop derivatives to extend protection.
Q5: When are the patents in this family expected to expire, and what implications does this have?
A5: Primary patents typically expire around 2019–2024, opening opportunities for generics, while secondary patents may extend market exclusivity.
References
-
U.S. Patent 5,859,037. Racemic and optically active 2-aryloxy-2-arylalkanoic acids and their derivatives. Eli Lilly and Company, 1999.
-
Patent family documents, including US 6,417,148 and US 6,986,999.
-
FDA Drug Approvals and IND filings for related compounds.
-
Patent landscape reports on NSAID patenting strategies (e.g., Forbes et al., 2010).
This professional analysis aims to equip pharmaceutical developers, patent strategists, and legal professionals with an in-depth understanding of U.S. Patent 5,859,037, highlighting its technical breadth, strategic relevance, and impact on the drug patenting landscape.
